Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.45) by 68.68 percent. This is a 76.27 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $63.74 million which beat the analyst consensus estimate of $14.35 million by 344.19 percent. This is a 147.98 percent increase over sales of $25.71 million the same period last year.